Strong Sobi With New Asset: A Takeover Target For Sanofi?

 
• By Eleanor Malone
  
Generate a summary of this article
Listen to this article
Beta

Swedish rare diseases specialist Sobi has reported strong financials and the acquisition of a rare disease candidate on the verge of US approval. Could partner Sanofi pop the question soon?

SC1807_Cat-Mouse_521299648_1200.jpg
Could Sobi's latest deal make it a juicier target?

With Sobi announcing the acquisition of late-stage orphan drug candidate emapalumab from NovImmune SA just two days after posting better than expected second-quarter sales, concerns about its sustainability are abating somewhat. Long-touted as a potential takeover target for a larger company operating in the rare disease space, Sobi is looking more and more appropriate for Sanofi.

Following completion of its acquisition of Sobi's hemophilia partner Bioverativ Inc. in March 2018, Sanofi had already become a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.